3 min read
The Psychedelic Setback: What MDMA Rejection Taught Drug Developers
In August 2024, the FDA declined to approve MDMA-assisted therapy for post-traumatic stress disorder. The decision...
Meet Veristat in Munich at BIO EUROPE 2023, 6-8 November 2023
With nearly 30 years of experience in clinical trial planning and execution, Veristat is equipped to support any development program.
If you are transitioning your compound into clinical trials, you need the right partner to guide your planning and decision-making. Whether you are preparing your IND/CTA, or you are looking to recruit patients quickly to get your early phase trials running, or just need medical writing or biostatistical support for your programs – Veristat can help.
As a versatile CRO and consultancy, we provide impactful solutions on a full-service or functional service basis, integrating strategic planning, regulatory expertise, and clinical trial execution to rapidly advance the most complex or novel therapies.
We are…Bold. Scientific. Versatile. Veristat.
Conference Details
Website: BIO EUROPE 2023
Schedule A Meeting
Veristat team member, Antonia Hernandez, Senior Business Development Director, will be at the venue, ready to listen to your needs and share Veristat’s expertise.
Meet with us at BIO EUROPE 2023 by filling out the form below.
9 min read
Monthly FDA Guidance and Regulatory News Review - March 2026
Apr 6, 2026 Veristat Blog
March 2026 regulatory updates underscore newly published final and draft guidances focused on real-world data, safety...